Locations:

Cleveland Clinic Performs World’s First DBS Surgery for Stroke Recovery

Patient doing well, stimulation to start in coming weeks

twitter-170104-17-neu-504-machado-650×450

Cleveland Clinic has performed the first deep brain stimulation (DBS) surgery in a patient for the purpose of restoring motor function following ischemic stroke.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

During a six-hour procedure on Dec. 19, 2016, a team led by Andre Machado, MD, PhD, implanted DBS electrodes in the cerebellum of the patient, who has severe post-stroke residual hemiparesis despite previous physical therapy. The patient has been discharged home feeling well and in stable condition.

Over the next few weeks, following adequate healing and recovery from the brain surgery, the patient will undergo physical therapy. After a few weeks of rehabilitation, the DBS device connected to the implanted electrodes will be turned on as the patient continues physical therapy. The patient will be monitored and evaluated regularly to determine whether and how DBS can enhance the effects of physical therapy.

The first-in-human operation is the initial case in an NIH-supported Cleveland Clinic trial of DBS for stroke recovery detailed previously on Consult QD.

“If this research succeeds, it is a new hope for patients who have remained paralyzed after a stroke,” says Dr. Machado, Chairman of Cleveland Clinic’s Neurological Institute and a neurosurgeon specializing in neuromodulation. “It is an opportunity to allow our patients to rehabilitate and gain function and independence. Our knowledge to date shows that deep brain stimulation can help the brain reorganize and adapt beyond what physical therapy alone can do. Our study’s goal is to boost rehabilitation outcomes beyond what physical therapy alone could achieve.”

More details about this initial case in the trial are available in a new Time magazine feature. Dr. Machado (shown in the foreground of the above photo) discusses the trial’s rationale and goals in this short Consult QD video.

Advertisement

Related Articles

mosquito on human skin

Rare New Neuroinvasive Threat Identified for Patients on B Cell-Depleting Therapy

Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies

Head shots of Susan Linder and Karen Green
November 3, 2026/Neurosciences/Podcast

Connecting Neuro Rehab Research and Clinical Care (Podcast)

Advanced technologies are changing expectations about what’s possible

illustration of street entrance to a hospital emergency area

Architecture as a Therapeutic Tool: Acute Stroke Care in Our New Neurological Building

A rare opportunity to design for speed, care coordination, recovery and continuous monitoring

Doctor and hospital tech standing next to an older patient in a hospital bed

Inpatient Program Reduced Medication Errors in Patients With Parkinson’s Disease

Multidisciplinary, proactive approach also improved discharge outcomes

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

Ad